Seegnal appoints Bibi-Aviv as CEO

Executive Summary

• Seegnal Inc. has appointed Elad Bibi-Aviv as its new Chief Executive Officer, effective December 16, 2025.
• Bibi-Aviv succeeds Eyal Schneid, who transitions to the role of General Manager of Seegnal E-Health Ltd., the company's Israeli operating subsidiary.
• The Board of Directors approved the grant of stock options to Bibi-Aviv to purchase up to 1,359,571 common shares as part of his compensation package.

Key Details

• CEO Appointment: Elad Bibi-Aviv, Esq., appointed CEO effective Dec. 16, 2025.
• Predecessor: Eyal Schneid steps down as CEO and assumes the role of General Manager of Seegnal E-Health Ltd.
• Executive Background: Bibi-Aviv is a two-time exit entrepreneur with experience in AI, fintech, biotech, and healthtech. He previously founded and served as CEO of Covary (an insurtech company acquired by a U.S. carrier) and led operations at NeuroKaire (an AI-driven healthtech provider).
• Stock Option Grant: The Board approved options for Bibi-Aviv to purchase up to 1,359,571 common shares.
  • Exercise Price: $0.80 per share.
  • Expiration: 10 years from the date of grant.
  • Conditions: Subject to the equity incentive plan, Option agreement, and TSX Venture Exchange requirements.
• Strategic Outlook: Chairman Nir Dor highlighted Bibi-Aviv's experience in building AI companies and selling to U.S. healthcare providers as key to accelerating Seegnal's global expansion and cost-saving initiatives for insurers.

Notable Quotes

• Nir Dor, Chairman: "We are delighted to welcome Elad Bibi-Aviv to Seegnal's leadership team. His proven experience in building AI companies and successfully selling to health care providers in the U.S. positions him perfectly to lead Seegnal through its next phase of growth. We are confident that under his leadership, Seegnal will accelerate its expansion and bring its life-saving platform to clinicians and pharmacists worldwide, while simultaneously delivering major cost savings to insurance carriers and HMOs by reducing unnecessary drug usage and hospitalization."